Extended life span is associated with insulin resistance in a transgenic mouse model of insulinoma secreting human islet amyloid polypeptide

American Journal of Physiology - Endocrinology and Metabolism

Volumn 286, Issue 3 49-3, 2004, Pages

  Andrikopoulos, Sofianos ^a   Hull, Rebecca L ^d   Verchere, C Bruce ^a   Wang, Feng ^a   Wilbur, Shani M ^a   Wight, Thomas N ^a   Marzban, Lucy ^b   Kahn, Steven E ^a,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b British Columbia Research Institute   (Canada)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^d NONE

Author keywords

Amylin; Euglycemic hyperinsulinemic clamp; Insulin sensitivity

Indexed keywords

AMYLIN; GLUCOSE; INSULIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CROSS BREEDING; EUGLYCEMIC HYPERINSULINEMIC CLAMP; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; GLUCOSE METABOLISM; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; INSULINOMA; LIFESPAN; LIPID DIET; MALE; MOUSE; MOUSE STRAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; TRANSGENIC MOUSE;

EID: 1442276284     PISSN: 01931849     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpendo.00137.2003     Document Type: Article

References (48)

1. An T and Kaye GI. Amyloid formation in insulinoma. Arch Pathol Lab Med 102: 227-232, 1978.
2. Andrikopoulos S, Verchere CB, Teague JC, Howell WM, Fujimoto WY, Wight TN, and Kahn SE. Two novel immortal pancreatic beta-cell lines expressing and secreting human islet amyloid polypeptide do not spontaneously develop islet amyloid. Diabetes 48: 1962-1970, 1999.
3. Andrikopoulos S, Verchere CB, Terauchi Y, Kadowaki T, and Kahn SE. β-Cell glucokinase deficiency and hyperglycemia are associated with reduced islet amyloid deposition in a mouse model of type 2 diabetes. Diabetes 49: 2056-2062, 2000.
4. Anguiano M, Nowak RJ, and Lansbury PT Jr. Protofibrillar islet amyloid polypeptide permeabilizes synthetic vesicles by a pore-like mechanism that may be relevant to type II diabetes. Biochemistry 41: 11338-11343, 2002.
5. Baskin DG, Gorray KC, and Fujimoto WY. Immunocytochemical identification of cells containing insulin, glucagon, somatostatin, and pancreatic polypeptide in the islets of Langerhans of the guinea pig pancreas with light and electron microscopy. Anat Rec 208: 567-578, 1984.
6. Bergman RN, Finegood DT, and Ader M. Assessment of insulin sensitivity in vivo. Endocr Rev 6: 45-86, 1985.
7. Christofori G, Naik P, and Hanahan D. A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. Nature 369: 414-418, 1994.
8. Clark A, Saad MF, Nezzer T, Uren C, Knowler WC, Bennett PH, and Turner RC. Islet amyloid polypeptide in diabetic and non-diabetic Pima Indians. Diabetologia 33: 285-289, 1990.
9. Clark A, Wells CA, Buley ID, Cruickshank JK, Vanhegan RI, Matthews DR, Cooper GJS, Holman RR, and Turner RC. Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res 9: 151-159, 1988.
10. Cohen RM, Given BD, Licinio-Paixao J, Provow SA, Rue PA, Frank BH, Root MA, Polonsky KS, Tager HS, and Rubenstein AH. Proinsulin radioimmunoassay in the evaluation of insulinomas and familial hyperproinsulinemia. Metabolism 35: 1137-1146, 1986.
11. Cooper GJS, Willis AC, Clark A, Turner RC, Sim RB, and Reid KBM. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 84: 8628-8632, 1987.
12. Cornish J, Callon KE, King AR, Cooper GJ, and Reid IR. Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice. Am J Physiol Endocrinol Metab 275: E694-E699, 1998.
13. D'Alessio DA, Verchere CB, Kahn SE, Hoagland V, Baskin DG, Palmiter RD, and Ensinck JW. Pancreatic expression and secretion of human IAPP in a transgenic mouse. Diabetes 43: 1457-1461, 1994.
14. Drews R, Drohan WN, and Lubon H. Transgene detection in mouse tail digests. Biotechniques 17: 866-867, 1994.
15. Efrat S, Linde S, Kofod H, Spector D, Delannoy M, Grant S, Hanahan D, and Baekkeskov S. Beta-cell lines are derived from transgenic mice expressing a hybrid insulin gene-oncogene. Proc Natl Acad Sci USA 85: 9037-9041, 1988.
16. Escobar O, Mizuma H, Sothern MS, Blecker U, Udall JN Jr, Suskind RM, Hilton C, and Vargas A. Hepatic insulin clearance increases after weight loss in obese children and adolescents. Am J Med Sci 317: 282-286, 1999.
17. Gebre-Medhin S, Mulder H, Pekny M, Westermark G, Tornell J, Westermark P, Sundler F, Ahren B, and Betsholtz C. Increased insulin secretion and glucose tolerance in mice lacking islet amyloid polypeptide (amylin). Biochem Biophys Res Commun 250: 271-277, 1998.
18. Hanahan D. Heritable formation of pancreatic β-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. Nature 315: 115-122, 1985.
19. Higham CE, Hull RL, Lawrie L, Shennan KI, Morris JF, Birch NP, Docherty K, and Clark A. Processing of synthetic pro-islet amyloid polypeptide (proIAPP) "amylin" by recombinant prohormone convertase enzymes, PC2 and PC3, in vitro. Eur J Biochem 267: 4998-5004, 2000.
20. Hoppener JWM, Oosterwijk C, Nieuwenhuis MG, Posthuma G, Thijssen JHH, Vroom TM, Ahren B, and Lips CJM. Extensive islet amyloid formation is induced by development of Type II diabetes mellitus and contributes to its progression: pathogenesis of diabetes in a mouse model. Diabetologia 42: 427-434, 1999.
21. Jaikaran ET, Nilsson MR, and Clark A. Pancreatic beta-cell granule peptides form heteromolecular complexes which inhibit islet amyloid polypeptide fibril formation. Biochem J 2003. Immediate publication, doi: 10.1042/BJ20030852.
22. Janciauskiene S, Eriksson S, Carlemalm E, and Ahren B. B cell granule peptides affect human islet amyloid polypeptide (IAPP) fibril formation in vitro. Biochem Biophys Res Commun 236: 580-585, 1997.
23. Janson J, Ashley RH, Harrison D, McIntyre S, and Butler PC. The mechanism of islet amyloid polypeptide toxicitiy is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 48: 491-498, 1999.
24. Kahn SE, Andrikopoulos S, and Verchere CB. Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 48: 241-253, 1999.
25. Kahn SE, D'Alessio DA, Schwartz MW, Fujimoto WY, Ensinck JW, Taborsky GJ Jr, and Porte D Jr. Evidence of cosecretion of islet amyloid polypeptide and insulin by β-cells. Diabetes 39: 634-638, 1990.
26. Kahn SE, Leonetti DL, Prigeon RL, Boyko EJ, Bergstrom RW, and Fujimoto WY. Proinsulin as a marker for the development of NIDDM in Japanese-American men. Diabetes 44: 173-179, 1995.
27. Knaack D, Fiore DM, Surana M, Leiser M, Laurance M, FuscoDeMane D, Hegre OD, Fleischer N, and Efrat S. Clonal insulinoma cell line that stably maintains correct glucose responsiveness. Diabetes 43: 1413-1417, 1994.
28. Kudva YC, Mueske C, Butler PC, and Eberhardt NL. A novel assay in vitro of human islet amyloid polypeptide amyloidogenesis and effects of insulin secretory vesicle peptides on amyloid formation. Biochem J 331: 809-813, 1998.
29. Leighton B and Cooper GJS. Pancreatic amylin and calcitonin generelated peptide cause resistance to insulin in skeletal muscle in vitro. Nature 335: 632-635, 1988.
30. Lorenzo A, Razzaboni B, Weir GC, and Yankner BA. Pancreatic islet cell toxicity of amylin associated with type 2-diabetes mellitus. Nature 368: 756-760, 1994.
31. Morgan DR and Lazarow A. Immunoassay of insulin: two antibody system: plasma insulin levels of normal, subdiabetic, and diabetic rats. Diabetes 12: 115-126, 1963.
32. Nishi M, Chan SJ, Nagamatsu S, Bell GI, and Steiner DF. Conservation of the sequence of islet amyloid polypeptide in five mammals is consistent with its putative role as an islet hormone. Proc Natl Acad Sci USA 86: 5738-5742, 1989.
33. O'Brien TD, Butler AD, Roche PC, Johnson KH, and Butler PC. Islet amyloid polypeptide in human insulinomas. Evidence for intracellular amyloidogenesis. Diabetes 43: 329-336, 1994.
34. Percy AJ, Trainor DA, Rittenhouse J, Phelps J, and Koda JE. Development of sensitive immunoassays to detect amylin and amylin-like peptides in unextracted plasma. Clin Chem 42: 576-585, 1996.
35. Poitout V, Stout LE, Armstrong MB, Walseth TF, Sorenson RL, and Robertson RP. Morphological and functional characterization of βTC-6 cells-an insulin-secreting cell line derived from transgenic mice. Diabetes 44: 306-313, 1995.
36. Porte D Jr and Kahn SE. Hyperproinsulinemia and amyloid in NIDDM: clues to etiology of islet β-cell dysfunction? Diabetes 38: 1333-1336, 1989.
37. vy/a mice expressing human islet amyloid polypeptide. Diabetes 47: 743-750, 1998.
38. Stridsberg M, Eriksson B, Lundqvist G, Skogseid B, Wilander E, and Oberg K. Islet amyloid polypeptide (IAPP) in patients with neuroendocrine tumours. Regul Pept 55: 119-131, 1995.
39. Verchere CB, D'Alessio DA, Palmiter RD, and Kahn SE. Transgenic mice overproducing human islet amyloid polypeptide have increased insulin storage and secretion in vitro. Diabetologia 37: 725-728, 1994.
40. Verchere CB, D'Alessio DA, Palmiter RD, Weir GC, Bonner-Weir S, Baskin DG, and Kahn SE. Islet amyloid formation associated with hyperglycemia in transgenic mice with pancreatic beta cell expression of human islet amyloid polypeptide. Proc Natl Acad Sci USA 93: 3492-3496, 1996.
41. Wang J, Xu J, Finnerty J, Furuta M, Steiner DF, and Verchere CB. The prohormone convertase enzyme 2 (PC2) is essential for processing pro-islet amyloid polypeptide at the NH2-terminal cleavage site. Diabetes 50: 534-539, 2001.
42. Ward WK, LaCava EC, Paquette TL, Beard JC, Wallum BJ, and Porte D Jr. Disproportionate elevation of immunoreactive proinsulin in type 2 (non-insulin-dependent) diabetes mellitus and experimental insulin resistance. Diabetologia 30: 698-702, 1987.
43. Westermark GT, Gebre-Medhin S, Steiner DF, and Westermark P. Islet amyloid development in a mouse strain lacking endogenous islet amyloid polypeptide (IAPP) but expressing human IAPP. Mol Med 6: 998-1007, 2000.
44. Westermark GT, Steiner DF, Gebre-Medhin S, Engstrom U, and Westermark P. Pro islet amyloid polypeptide (ProIAPP) immunoreactivity in the islets of Langerhans. Ups J Med Sci 105: 97-106, 2000.
45. Westermark P, Engstrom U, Johnson KH, Westermark GT, and Betsholtz C. Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci USA 87: 5036-5040, 1990.
46. Westermark P, Engstrom U, Westermark GT, Johnson KH, Pemerth J, and Betsholtz C. Islet amyloid polypeptide (IAPP) and pro-IAPP immunoreactivity in human islets of Langerhans. Diabetes Res Clin Pract 7: 219-226, 1989.
47. Westermark P, Li ZC, Westermark GT, Leckstrom A, and Steiner DF. Effects of beta cell granule components on human islet amyloid polypeptide fibril formation. FEBS Lett 379: 203-206, 1996.
48. Westermark P, Wernstedt C, Wilander E, and Sletten K. A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas. Biochem Biophys Res Commun 140: 827-831, 1986.